Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.57 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.51 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.51 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.50 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.57 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31233227 | 1.00 | DRD2 (0.57) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| SCHEMBL383031 | 0.98 | SLC18A3 (0.59) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| SCHEMBL381572 | 0.98 | SLC18A3 (0.59) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| SCHEMBL4280 | 0.98 | SLC18A3 (0.59) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| Benzene SCHEMBL28198364 | 0.98 | SLC18A3 (0.59) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL3689510 | 0.94 | SLC18A3 (0.55) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| SCHEMBL3701789 | 0.92 | SLC18A3 (0.57) | DRD2DRD3SLC18A3SIGMAR1HTR2A | |
| Hydrochloric Acid SCHEMBL2173028 | 0.89 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL4573453 | 0.89 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 | |
| Hydrochloric Acid SCHEMBL30098419 | 0.89 | SLC18A3 (0.72) | SLC18A3SIGMAR1HTR3AJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4623914-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-10-01 | — | — | EP | disclosed |
| CN-120035438-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024109684-A1 | USE OF 8-HYDROXYQUINOLINE DERIVATIVE | 江苏亚虹医药科技股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| CN-118059101-A | Use of 8-hydroxyquinoline derivatives | 江苏亚虹医药科技股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4349815-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2024-04-10 | — | — | EP | disclosed |
| CN-117043141-A | 7-nitro-8-hydroxyquinoline derivative, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2022253152-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| EP-3356360-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-7381719-B2 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| CN-1305852-C | Diaryl ethers as opioid receptor antagonists | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | ELI LILLY AND COMPANY | 2006-09-28 | — | — | US | disclosed |
| CN-1681498-A | Diaryl ethers as opioid receptor antagonist | LILLY CO ELI (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246916-A1 | 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF | CYP3A7, UGT1A7, UGT2B7 | DRD2 3608/4885DRD3 4356/4885SIGMAR1 2226/4885 |
| US-20060217372-A1 | Diaryl ethers as opioid receptor antagonist | OPRM1, OPRL1, OPRD1 | DRD2 171/4885DRD3 54/4885SIGMAR1 10/4885 |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | DRD2 211/4885DRD3 240/4885SIGMAR1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.